1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Forest Labs Clinical Development Profile

Forest Labs Clinical Development Profile

  • February 2014
  • -
  • Industry Standard Research
  • -
  • 50 pages

ISR’s report provides a thorough analysis of Forest Laboratories’ R&D pipeline, clinical trial activity, patents, FDA submissions, and includes profiles of Forest’s key products.

What you will learn in this report:

How you can use this report:
- Drug sales and company financial condition over the past four years
- Number, length, and patient enrollment of clinical trials segmented by phase and trial type
- Current R&D pipeline overview
- Important aspects of Forest’s key products such as MOA, dosing, and interaction characteristics
- Pharmaceutical Companies: Identify the clinical and commercial status of competing compounds and understand how these will affect the launch of similar products.
- For Service Providers: Learn Forest’s strategic direction and better understand their clinical development pipeline.

Clinical trial activity
Data used in this analysis was pulled from ClinicalTrials.gov (www.clinicaltrials.gov) on 10 December 2013. The analysis includes all trials conducted by Forest Laboratories
listed on ClinicalTrials.gov.
Data/ clinical trials were segmented into three groups:
- Ongoing trials (N=51 trials)—these clinical studies are currently ongoing.
- Past 2 years (N=84 trials)—these trials were completed in the past two years.
- Historic trials (N=141 trials)—these trials were completed more than two years ago and were not analyzed for this report.
The analyses that follow center on only the 135 clinical trials that are currently ongoing and those that have been completed in the past two years.

For definitional purposes:
- An “ongoing” trial is a trial with an ending date after 1 December 2013.
- A “recently completed” trial is one with an ending date occurring after 1 December
2011 but before 1 December 2013 (past two years).

Table Of Contents

Forest Labs Clinical Development Profile
Table of Contents

Copyright and Usage Guidelines ..3
Background and strategy .4
Financial condition .10
Drug sales .11
Stock performance ...12
RandD pipeline overview ..13
Clinical trial activity 14
Number of clinical trials, by phase ...15
Study type distribution (e.g. interventional) 15
Interventional trials, by phase .16
Observational trials, by phase ..16
Industry-funded study type distribution ..17
Industry-funded interventional trials, by phase ..17
Industry-funded observational trials, by phase ...18
Average trial length, by phase .19
Average interventional trial length, by phase .20
Average observational trial length, by phase ..20
Average industry-sponsored interventional trial length, by phase .21
Average industry-sponsored observational trial length, by phase ..22
Projected vs. actual ongoing trial length, by phase .23
Projected vs. actual ongoing interventional trial length, by phase .23
Projected vs. actual ongoing observational trial length, by phase ..24
Projected vs. actual ongoing industry-sponsored interventional trial length, by phase .24
Average enrollment by phase ..25
Interventional enrollment, by phase ...25
Observational enrollment, by phase 26
Industry-sponsored, interventional trial enrollment, by phase ...26
Industry-sponsored, observational trial enrollment, by phase 27
Patents .28
FDA submissions 32
Approved drugs 32
Discontinued drugs ...34
Key product profiles ...36
Bystolic .36
Daliresp 37
Lexapro 38
Linzess ..39
Namenda ..40
Namenda XR .41
Savella ..42
Teflaro ..43
Tudorza 44
Viibryd ..45
Summary 46
RandD spending ..46
Clinical development highlights ...46
Forest: key compound MOA and trial overview ..47
Aptalis: key compound MOA and trial overview .48
About Industry Standard Research 50

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 202

Bioinformatics Market by Sector (Molecular Medicine, Agriculture, Forensic, Animal, Research & Gene Therapy), Product (Sequencing Platforms, Knowledge Management & Data Analysis) & Application (Genomics, Proteomics & Metabolomics) - Global Forecast to 202

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global bioinformatics market is projected to reach USD 16.18 billion by 2021 from USD 6.21 billion in 2016, growing at a CAGR of 21.1% during the forecast period. In this report, the bioinformatics ...

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.